CELGENE CORPORATION | 95,79 Euro | -0,019 -0,02 % | |
| WKN: 881244 ISIN: US1510201049 Ticker-Symbol: CG3 | Frankfurt | 17.05.13 | 16:50 Uhr |
Branche PharmaAktienmarkt NASDAQ-100S&P 500 NASDAQ Biotech |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 14.05. | Celgene: Apremilast For Psoriatic Arthritis Offers Upside | 26 | Seeking Alpha | |
| 14.05. | Celgene Attains 52-Week High | 7 | Zacks | |
| 14.05. | Celgene Looks to Continue to Trade Above its Annual-High Share Price Today | 4 | SmarTrend | |
| 14.05. | Celgene verbleibt im Rausch der Höhenluft | 59 | GodmodeTrader.de | |
| 11.05. | Short Interest in Vertex Rises, in Celgene Falls | 34 | Benzinga.com | |
| 09.05. | Positive Data on Celgene's Apremilast | 30 | Zacks | |
| 07.05. | The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus | 230 | PR Newswire | |
| CHICAGO, May 7, 2013 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks... Mehr lesen zu: The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus | ||||
| 07.05. | Concert Pharmaceuticals, Celgene to develop deuterium-modified compounds | 9 | Pharma Bus Review | |
| 06.05. | UPDATE: Celgene's Says Apremilast Achieves Statistical Significant for Primary, Major Secondary Endpoints in Fourth Pivotal Phase III Study | 8 | Benzinga.com | |
| 06.05. | Celgene (CELG) Unit Achieves Statistical Significance in PALACE 4 | 4 | StreetInsider.com | |
| 06.05. | Concert Pharma teams up with Celgene, signs third agreement in a year | 3 | bizjournals | |
| 06.05. | Concert Pharma Reports Strategic Collaboration with Celgene | 12 | Benzinga.com | |
| 30.04. | The Zacks Analyst Blog Highlights: Merck, GlaxoSmithKline, VIVUS, Santarus and Celgene | 125 | PR Newswire | |
| CHICAGO, April 30, 2013 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events... Mehr lesen zu: The Zacks Analyst Blog Highlights: Merck, GlaxoSmithKline, VIVUS, Santarus and Celgene | ||||
| 29.04. | CHMP in Favor of Celgene's Revlimid | 17 | Zacks | |
| 29.04. | FORMA, Celgene team up on potential protein drugs | 12 | bizjournals | |
| 29.04. | FORMA, Celgene Announce Strategic Collaboration for Discovery, Development, Commercialization of Protein Homeostasis Targets | 8 | Benzinga.com | |
| 29.04. | FORMA Therapeutics, Celgene (CELG) Enter Protein Homeostasis Collaboration | 6 | StreetInsider.com | |
| 26.04. | Short Sellers Move into Celgene, Regeneron | 33 | Benzinga.com | |
| 26.04. | Barclays hebt das Kursziel für Celgene von $113 auf $132. | 172 | BörseGo | |
| Barclays hebt das Kursziel für Celgene von $113 auf $132.
(© BörseGo AG 2013 - Autor: Simon Hauser, Redakteur) Mehr lesen zu: Barclays hebt das Kursziel für Celgene von $113 auf $132. | ||||
| 26.04. | Celgene Int'l.: CHMP Adopts Positive Opinion For REVLIMID | 58 | AFX News | |
| SUMMIT (dpa-AFX) - Celgene International Sàrl (CELG) said the European
Medicines Agency's or EMA: Committee for Medicinal Products for Human Use or
CHMP has adopted a positive opinion for... Mehr lesen zu: Celgene Int'l.: CHMP Adopts Positive Opinion For REVLIMID | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| GILEAD SCIENCES | 43,30 | +2,44 % | Gilead gibt Wirkungsdaten aus Phase-2-Studie zu Idelalisib für nicht vorbehandelte chronische lymphatische Leukämie bekannt |
| STADA ARZNEIMITTEL | 33,555 | -0,93 % | STADA: Gute Zahlen und positive Analystenstimmen beflügeln Kurs |
| PFIZER | 22,565 | -1,03 % | Global Vision Selected by Pfizer for Worldwide Deployment of Automated Proofreading Solutions |
| VERTEX PHARMACEUTICALS | 61,72 | +3,50 % | VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report |
| CELESIO | 16,17 | -2,30 % | XFRA DIVIDEND INFORMATION - 17.05.2013 - 1 |
